Rivaroxaban

From Citizendium
Revision as of 11:23, 6 December 2009 by imported>Howard C. Berkowitz
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.
For more information, see: Coagulation.

In medicine, rivaroxaban is an anticoagulant that inhibits factor Xa.[1] Like warfarin, rivaroxaban is given orgally, but unlike warfarin rivaroxaban is administered in fixed doses without the need for coagulation monitoring.

History

Rivaroxaban was approved for use by the European Medicines Agency in 2009 "to prevent venous thromboembolism (VTE, the formation of clots in the veins) in adults who are undergoing surgery to replace a hip or knee."[2]

Rivaroxaban has not been approved by the Food and Drug Administration in the United States.

Pharmacology

Administration

Rivaroxaban is given orally

Distribution

Metabolism

Excretion

Toxicity

Clinical uses

Deep venous thrombosis

Rivaroxaban can prevent embolism and thrombosis during perioperative care according to randomized controlled trials with two weeks of therapy after knee arthoplasty[3] or 5 weeks of therapy after hip arthroplasty.[4][5]

External links

The most up-to-date information about Rivaroxaban and other drugs can be found at the following sites.


References